US FDA approves inebilizumab for the treatment of neuromyelitis optica spectrum disorder

Inebilizumab has been approved in the US specifically for the treatment of adult patients who are anti-aquaporin-4 antibody positive. It is only the second treatment to be approved in the US for the treatment of this rare autoimmune disease.

Source:

US Food and Drug Administration